BRIEF—MHRA backs Idorsia’s hypertension drug Jeraygo

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Jeraygo (aprocitentan) to treat hypertension (high blood pressure) in adults whose blood pressure cannot be adequately controlled by at least three other medicines (also known as resistant hypertension).

The new marketing authorization was granted in 106 days on January 8 to Idorsia Pharmaceuticals Deutschland GmbH under the International Recognition Procedure (IRP) Route B.

In July last year, the European Commission approved Swiss drug developer Idorsia’s Jeraygo for the same indication. It was also approved under the trade name Tryvio in March last year.